Latest News

Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.
Post-HSCT Defibrotide Does Not Reduce Sinusoidal Obstruction Syndrome

February 14th 2025

Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.

The analysis saw minimal evidence of increased relapse among patients with hematologic cancers and minimal residual disease vs those without.
UCBT Yields Excellent Efficacy Outcomes in Hematologic Malignancies

February 13th 2025

Clonal hematopoiesis may be associated with the early development of toxic events in patients with newly diagnosed multiple myeloma.
CHIP-Carrying Multiple Myeloma Correlates With More Aggressive Disease

February 4th 2025

Inflammation-induced epigenetic imprinting regulates intestinal stem cells
Inflammation-induced epigenetic imprinting regulates intestinal stem cells

January 28th 2025

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS

January 24th 2025

More News